DE60131265D1 - Pharmazeutische formulierungen für trockenpulverinhalatoren - Google Patents

Pharmazeutische formulierungen für trockenpulverinhalatoren

Info

Publication number
DE60131265D1
DE60131265D1 DE60131265T DE60131265T DE60131265D1 DE 60131265 D1 DE60131265 D1 DE 60131265D1 DE 60131265 T DE60131265 T DE 60131265T DE 60131265 T DE60131265 T DE 60131265T DE 60131265 D1 DE60131265 D1 DE 60131265D1
Authority
DE
Germany
Prior art keywords
dry powder
fraction
powder
fine particle
active ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60131265T
Other languages
English (en)
Other versions
DE60131265T2 (de
Inventor
John Nicholas Staniforth
David Alexander Vodden Morton
Rajbir Gill
Gaetano Brambilla
Rossella Musa
Lorenzo Ferrarini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectura Ltd
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60131265(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0009469.8A external-priority patent/GB0009469D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Application granted granted Critical
Publication of DE60131265D1 publication Critical patent/DE60131265D1/de
Publication of DE60131265T2 publication Critical patent/DE60131265T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
DE60131265T 2000-04-17 2001-04-17 Pharmazeutische formulierungen für trockenpulverinhalatoren Revoked DE60131265T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0009469 2000-04-17
GBGB0009469.8A GB0009469D0 (en) 2000-04-17 2000-04-17 Improvements in or relating to formalities for use in inhaler devices
EP00113608 2000-06-27
EP00113608 2000-06-27
PCT/GB2001/001751 WO2001078695A2 (en) 2000-04-17 2001-04-17 Pharmaceutical formulations for dry powder inhalers

Publications (2)

Publication Number Publication Date
DE60131265D1 true DE60131265D1 (de) 2007-12-20
DE60131265T2 DE60131265T2 (de) 2008-03-06

Family

ID=26071084

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60125344T Expired - Lifetime DE60125344T2 (de) 2000-04-17 2001-04-17 Formulierungen zur verwendung in inhalationsvorrichtungen
DE60123031T Expired - Lifetime DE60123031T2 (de) 2000-04-17 2001-04-17 Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets
DE60131265T Revoked DE60131265T2 (de) 2000-04-17 2001-04-17 Pharmazeutische formulierungen für trockenpulverinhalatoren

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE60125344T Expired - Lifetime DE60125344T2 (de) 2000-04-17 2001-04-17 Formulierungen zur verwendung in inhalationsvorrichtungen
DE60123031T Expired - Lifetime DE60123031T2 (de) 2000-04-17 2001-04-17 Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets

Country Status (32)

Country Link
US (4) US6884794B2 (de)
EP (6) EP1274406B1 (de)
JP (2) JP2003530425A (de)
KR (1) KR20030069047A (de)
CN (1) CN1424909A (de)
AT (5) ATE348603T1 (de)
AU (3) AU784719B2 (de)
BR (3) BR0110141A (de)
CA (3) CA2406119C (de)
CY (1) CY1107315T1 (de)
CZ (1) CZ301904B6 (de)
DE (3) DE60125344T2 (de)
DK (3) DK1719505T3 (de)
DZ (1) DZ3315A1 (de)
EE (1) EE05257B1 (de)
ES (3) ES2292576T3 (de)
GB (2) GB2363988A (de)
HU (4) HUP0300490A2 (de)
IL (1) IL152306A0 (de)
MA (1) MA26892A1 (de)
MX (3) MXPA02010213A (de)
MY (1) MY129384A (de)
NO (4) NO332025B1 (de)
NZ (1) NZ521887A (de)
PE (1) PE20011227A1 (de)
PL (3) PL204251B1 (de)
PT (3) PT1719505E (de)
SA (1) SA01220062B1 (de)
SI (2) SI1274406T1 (de)
SK (1) SK284248B6 (de)
TN (1) TNSN01060A1 (de)
WO (3) WO2001078694A2 (de)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
BR9917246A (pt) * 1999-03-05 2002-03-26 Chiesi Farma Spa Composições farmacêuticas avançadas em pó para inalação
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
US7744855B2 (en) 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
WO2002043702A2 (en) † 2000-11-30 2002-06-06 Vectura Limited Pharmaceutical compositions for inhalation
ES2334642T5 (es) 2000-11-30 2016-03-07 Vectura Limited Partículas para usar en una composición farmacéutica
EP2283818B1 (de) 2000-11-30 2017-08-02 Vectura Limited Herstellungsverfahren für Partikel zur Verwendung in einer Arrzneizusammensetzung
WO2002056948A1 (en) 2001-01-17 2002-07-25 Vectura Limited An inhaler device
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
US7931533B2 (en) 2001-09-28 2011-04-26 Igt Game development architecture that decouples the game logic from the graphics logics
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
AU2002330390A1 (en) * 2002-03-20 2003-09-29 Hosokawa Micron Corporation Method of manufacturing chemical-containing composite particles
FI116657B (fi) * 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
US20030235538A1 (en) * 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
MXPA05001903A (es) * 2002-08-21 2005-04-28 Norton Healthcare Ltd Composicion para inhalacion.
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1452179A1 (de) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
CA2522158C (en) * 2003-04-14 2018-03-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
WO2005004852A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
EP1643973A1 (de) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmazeutische zusammensetzungen enthaltend magnesiumstearat
EP1500390B1 (de) * 2003-07-25 2005-08-17 Ferring B.V. Pharmazeutische Desmopressin-Zubereitung als feste Darreichungsform und Methode zu ihrer Herstellung
CN1826099B (zh) * 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005025535A2 (en) * 2003-09-15 2005-03-24 Vectura Limited Methods for preparing pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
WO2005053647A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Medical product containing tiotropium
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
SE0303569L (sv) * 2003-12-03 2005-06-04 Microdrug Ag DPI för avlämning av fuktkänsliga medikament
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
DK2708225T3 (en) 2004-04-23 2019-04-08 Cydex Pharmaceuticals Inc DPI formulation containing sulfoalkyl ether cyclodextrin
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
NZ556709A (en) 2005-02-10 2009-09-25 Glaxo Group Ltd Process for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
EP1857114A1 (de) * 2005-03-09 2007-11-21 Ono Pharmaceutical Co., Ltd. Teilchen und dieses teilchen enthaltende zubereitung
JP2008534611A (ja) * 2005-03-30 2008-08-28 シェーリング コーポレイション 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP1944018A1 (de) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Mikronisierte Partikel mit niedrigdosierten Wirkstoffen für Pulverzubereitungen zur Inhalation
SI2425820T1 (sl) 2007-02-11 2015-07-31 Map Pharmaceuticals Inc Metoda terapevtske uporabe dhe za hitro lajšanje migrene s čim manj neželenimi učinki
NZ582586A (en) 2007-07-21 2011-12-22 Albany Molecular Res Inc 5-pyridinone substituted indazoles
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
EP2292089A1 (de) 2008-01-11 2011-03-09 Astellas Pharma Inc. Modelltier mit hodenschmerzen oder beschwerden bei die hoden betreffenden handlungen und häufigem harndrang
EP2476680B1 (de) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinon)-substituierte Pyrido-Indole
EP2080508A1 (de) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Trockenpulverformulierung mit einem anticholinergischen Arzneimittel
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP2191821A1 (de) * 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Mikropartikel enthaltend ein Salz von 8-Hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone mit verbesserten Adhesionseigenschaften zur Trockenpulver-Inhalation
CA2750777C (en) 2009-01-26 2018-04-03 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010097188A1 (en) 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
LT2400950T (lt) 2009-02-26 2019-08-26 Glaxo Group Limited Farmacinės kompozicijos, apimančios 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzil)oksi]etoksi}heksil)amino]-1-hidroksetil}-2-(hidroksimetil)fenolį
US20120101077A1 (en) * 2009-04-24 2012-04-26 Schering Corporation Agglomerate formulations useful in dry powder inhalers
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2360147A1 (de) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Verfahren zur Herstellung von kristallinen Partikeln von einem Salz von 8-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-chinolinon (Carmoterol)
EP2552424B1 (de) 2010-04-01 2018-05-09 Chiesi Farmaceutici S.p.A. Verfahren zur herstellung von trägerteilchen für trockenpulver zur inhalation
NO2560611T3 (de) 2010-04-21 2018-06-02
BR112012027900A2 (pt) 2010-04-30 2020-05-12 Alexion Pharmaceuticals, Inc. Anticorpos anti-c5a e métodos para usar os anticorpos
WO2011152804A2 (en) 2010-06-03 2011-12-08 Mahmut Bilgic Process for dry powder formulations
UA107499C2 (uk) 2010-06-22 2015-01-12 Chiesi Farm Spa Склад сухого порошку, який містить антимускариновий засіб
SG187258A1 (en) * 2010-08-03 2013-03-28 Chiesi Farma Spa Dry powder formulation comprising a phosphodiesterase inhibitor
US20130177651A1 (en) * 2010-09-03 2013-07-11 Pharmaterials Limited Pharmaceutical Composition Suitable for Use in a Dry Powder Inhaler
JP5877204B2 (ja) 2010-09-29 2016-03-02 パルマトリックス，インコーポレイテッド 吸入用の一価金属カチオン乾燥粉末
RU2580890C2 (ru) 2010-09-30 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Применение стеарата магния в составах сухого порошка для ингаляции
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
TR201105367A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
TR201205852A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Geliştirilmiş yeni kuru toz formülasyonu.
WO2013109208A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Formulations comprising formoterol as active agent
WO2013109211A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
WO2013109214A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
SI2806855T1 (sl) 2012-01-25 2018-11-30 Chiesi Farmaceutici S.P.A. Suha praškasta formulacija, ki obsega kortikosteroid in beta-adrenergik za dajanje z inhalacijo
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
UA115544C2 (uk) 2012-03-13 2017-11-27 Респіверт Лімітед Спосіб підвищення стабільності до хімічного розкладання фармацевтичної композиції та застосування стабілізуючого агента у фармацевтичній коипозиції
WO2013153146A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) * 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US11052202B2 (en) 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
HUE052275T2 (hu) 2013-01-28 2021-04-28 Incozen Therapeutics Pvt Ltd Eljárások autoimmun, légzõszervi és gyulladásos rendellenességek kezelésére roflumilaszt N-oxid inhalálásával
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP2821061B1 (de) * 2013-07-01 2017-12-20 Arven Ilac Sanayi Ve Ticaret A.S. Neue präparate fur atemwege
NZ715797A (en) * 2013-07-11 2020-06-26 Chiesi Farm Spa Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
WO2015049519A2 (en) * 2013-10-02 2015-04-09 Vectura Limited Method and apparatus
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
EP3060205A4 (de) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolynderivate und zugehörige verfahren für bildgebung und behandlung
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
EP2957552B1 (de) 2014-06-16 2020-01-22 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterolformulierungen
EP3166641B1 (de) 2014-07-09 2018-09-12 Arven Ilac Sanayi Ve Ticaret A.S. Verfahren zur herstellung von formulierungen zur inhalation
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
RU2693201C1 (ru) * 2015-06-23 2019-07-01 Шлюмберже Текнолоджи Б.В. Распознание расклинивающего агента с помощью мобильного устройства
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
PT3620176T (pt) 2015-11-16 2021-09-28 Chiesi Farm Spa Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
SG10201912090UA (en) * 2015-11-16 2020-02-27 Chiesi Farm Spa A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
US10960152B2 (en) * 2015-12-24 2021-03-30 Philip Morris Products S.A. Nicotine particle capsule
EP3506894B1 (de) 2016-08-31 2023-08-23 The General Hospital Corporation Macrophagen/mikroglia bei nervenentzündungen im zusammenhang mit neurodegenerativen erkrankungen
CN110582269B (zh) * 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
BR112019023386A2 (pt) 2017-05-11 2020-06-16 Chiesi Farmaceutici S.P.A. Processo para preparar uma formulação em pó para inalação para uso em um inalador de pó seco
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
EP3652210A1 (de) 2017-07-14 2020-05-20 CytomX Therapeutics, Inc. Anti-cd166-antikörper und verwendungen davon
CN111107788B (zh) * 2017-07-26 2023-12-19 深圳帧观德芯科技有限公司 具有空间扩展性x射线源的x射线成像系统
AU2018306612C1 (en) 2017-07-27 2023-11-09 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
WO2019060604A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
WO2019060797A1 (en) 2017-09-22 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. PROCESS FOR PRODUCING POWDERS FOR INHALING
WO2019067708A1 (en) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE
JP2021529771A (ja) * 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤
WO2020020957A1 (en) 2018-07-27 2020-01-30 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
JP2021536467A (ja) 2018-09-06 2021-12-27 インノファーマスクリーン インコーポレイテッド 喘息またはパーキンソン病の処置のための方法および組成物
MX2021004643A (es) 2018-10-30 2021-05-28 Chiesi Farm Spa Aparato para administrar farmacos a pacientes ventilados mecanicamente.
CN113412117A (zh) 2018-12-12 2021-09-17 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
CA3138530A1 (en) 2019-04-29 2020-11-05 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
CN114514020A (zh) 2019-09-24 2022-05-17 奇斯药制品公司 用于吸入用干粉制剂的新型载体颗粒
JP2023523601A (ja) 2020-04-24 2023-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ１９抗体及びその使用
WO2021237109A1 (en) 2020-05-22 2021-11-25 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
WO2022215054A1 (en) 2021-04-09 2022-10-13 Takeda Pharmaceutical Company Limited Antibodies targeting complement factor d and uses therof
US20230111279A1 (en) 2021-04-26 2023-04-13 Millennium Pharmaceuticals, Inc. Anti-clec12a antibodies and uses thereof
WO2022232035A1 (en) 2021-04-26 2022-11-03 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1571629A (en) 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
EP0441740B1 (de) 1990-01-29 1993-09-22 Ciba-Geigy Ag Verfahren und Vorrichtung zur Dosierung eines feinkörnigen Pulvers
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
CA2115444C (en) 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9700136D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6475462B1 (en) * 1997-09-30 2002-11-05 Mortimer Technology Holdings Limited Process and apparatus for treating particulate matter
WO1999047196A1 (en) * 1998-03-16 1999-09-23 Inhale Therapeutic Systems, Inc. Aerosolized active agent delivery
HU226164B1 (en) * 1998-11-13 2008-05-28 Jagotec Ag Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation
GB9826783D0 (en) * 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
BR9917246A (pt) * 1999-03-05 2002-03-26 Chiesi Farma Spa Composições farmacêuticas avançadas em pó para inalação
CA2389219C (en) * 1999-10-29 2009-06-23 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US7744855B2 (en) * 2000-06-27 2010-06-29 Vectura Limited Method of making particles for use in a pharmaceutical composition

Also Published As

Publication number Publication date
CA2405767C (en) 2011-07-05
WO2001078695A3 (en) 2002-03-14
DE60125344T2 (de) 2007-07-19
NZ521887A (en) 2004-06-25
CA2406119A1 (en) 2001-10-25
BR0110141A (pt) 2003-01-28
EP1829533A3 (de) 2007-10-31
EP1274406A2 (de) 2003-01-15
US6884794B2 (en) 2005-04-26
CZ20023437A3 (cs) 2003-02-12
EP2272508B1 (de) 2020-03-25
NO20024973L (no) 2002-12-16
GB0109431D0 (en) 2001-06-06
SI1274406T1 (sl) 2007-02-28
SK284248B6 (sk) 2004-12-01
NO342999B1 (no) 2018-09-24
SK14912002A3 (sk) 2003-03-04
GB0109432D0 (en) 2001-06-06
NO20024980D0 (no) 2002-10-16
EP2272508A2 (de) 2011-01-12
NO332025B1 (no) 2012-05-29
EP1829533B1 (de) 2011-06-22
HUP0300593A2 (hu) 2003-09-29
MY129384A (en) 2007-03-30
MA26892A1 (fr) 2004-12-20
CA2405767A1 (en) 2001-10-25
BR0110139A (pt) 2002-12-31
PL358875A1 (en) 2004-08-23
EP1829533A2 (de) 2007-09-05
AU4859501A (en) 2001-10-30
ATE513542T1 (de) 2011-07-15
MXPA02010212A (es) 2004-06-29
CA2406119C (en) 2009-07-07
WO2001078694A3 (en) 2002-03-14
DE60123031T2 (de) 2007-03-08
HUP1300117A2 (en) 2003-07-28
EP1719505A2 (de) 2006-11-08
EP1276472A2 (de) 2003-01-22
EP1276472B1 (de) 2006-12-20
WO2001078694A2 (en) 2001-10-25
DZ3315A1 (fr) 2001-10-25
PL358640A1 (en) 2004-08-09
SI1719505T1 (sl) 2011-12-30
US20050201950A1 (en) 2005-09-15
ATE377416T1 (de) 2007-11-15
EP1719505A3 (de) 2007-07-18
NO20024971L (no) 2002-12-17
CA2406201A1 (en) 2001-10-25
CZ301904B6 (cs) 2010-07-28
TNSN01060A1 (fr) 2005-11-10
HUP0300499A2 (en) 2003-07-28
JP2003530425A (ja) 2003-10-14
NO20110885L (no) 2002-12-17
PL359289A1 (en) 2004-08-23
US20120308613A1 (en) 2012-12-06
AU4858101A (en) 2001-10-30
EP1274406B1 (de) 2006-09-13
IL152306A0 (en) 2003-05-29
ATE339195T1 (de) 2006-10-15
MXPA02010213A (es) 2005-07-01
US20030175214A1 (en) 2003-09-18
ES2272473T3 (es) 2007-05-01
EE05257B1 (et) 2010-02-15
NO20024980L (no) 2002-12-17
NO20024973D0 (no) 2002-10-16
PL204251B1 (pl) 2009-12-31
DE60123031D1 (de) 2006-10-26
DE60131265T2 (de) 2008-03-06
DK1719505T3 (da) 2011-12-05
NO336687B1 (no) 2015-10-19
AU784719B2 (en) 2006-06-01
PT1719505E (pt) 2011-10-24
CA2406201C (en) 2011-03-22
ATE348603T1 (de) 2007-01-15
US7223748B2 (en) 2007-05-29
PE20011227A1 (es) 2002-01-07
CY1107315T1 (el) 2012-11-21
ES2292576T3 (es) 2008-03-16
WO2001078693A3 (en) 2002-01-17
GB2363988A (en) 2002-01-16
HUP0300490A2 (en) 2003-07-28
BR0110301A (pt) 2003-12-30
ATE521340T1 (de) 2011-09-15
HU229270B1 (en) 2013-10-28
MXPA02010218A (es) 2003-05-23
EP1276473A2 (de) 2003-01-22
WO2001078695A2 (en) 2001-10-25
ES2275669T3 (es) 2007-06-16
EP2272508A3 (de) 2012-01-18
PT1274406E (pt) 2007-01-31
SA01220062B1 (ar) 2006-11-05
PT1276472E (pt) 2007-02-28
DK1274406T3 (da) 2007-01-22
CN1424909A (zh) 2003-06-18
DK1276472T3 (da) 2007-04-16
EP1719505B1 (de) 2011-08-24
HU230464B1 (hu) 2016-07-28
GB2363987A (en) 2002-01-16
NO20024971D0 (no) 2002-10-16
HU229797B1 (en) 2014-07-28
US20030180227A1 (en) 2003-09-25
US8182791B2 (en) 2012-05-22
HUP0300593A3 (en) 2006-07-28
AU2001258343A1 (en) 2001-10-30
WO2001078693A2 (en) 2001-10-25
EP1276473B1 (de) 2007-11-07
KR20030069047A (ko) 2003-08-25
JP2012255035A (ja) 2012-12-27
PL204213B1 (pl) 2009-12-31
DE60125344D1 (de) 2007-02-01
EE200200593A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
DE60131265D1 (de) Pharmazeutische formulierungen für trockenpulverinhalatoren
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
JO3102B1 (ar) صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
Yang et al. Drug delivery performance of the mometasone furoate dry powder inhaler
TW200602054A (en) Use of compounds in a dry powder inhaler
JP2002161030A (ja) 異なる粒径をもった混合粉体の吸入方法
TH75699B (th) สูตรผสมทางเภสัชกรรมสำหรับเครื่องพ่นยาผงแห้ง ซึ่งประกอบรวมด้วยส่วนประกอบออกฤทธิ์ที่มีความแรงของขนาดยาต่ำ
TH101600B (th) สูตรผสมทางเภสัชกรรมสำหรับยาสูดดมชนิดผงแห้งในรูปของฮาร์ดเพลเล็ท

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation